Search results for: 'software-as-a-service'

21 Mar 2025  |  Global  |  Market Research

Pharmaceutical Clinical Contract Peripheral Services, Global, 2025–2030

The CRO Industry is Witnessing Transformational Growth Due to Industry Convergence and an Increasing Reliance on the Functional Service Provider (FSP) Model

Infographics

×

As trial volumes normalize after the COVID-19 pandemic, pharma and biopharma companies are re-focusing on their drug development pipelines. As a result, the market has been creating an increasing number of clinical trial outsourcing opportunities for CROs, with these service providers also refining their processes to ensure better clinical trial tu...

The regulatory technology market in life sciences has, over the last five years, quietly transformed from a back-office category dominated by document repositories and submission publishing tools to one of the most consequential software segments serving the pharmaceutical, biotech, and medical device industries. What started in the late 1990s as a...

The global pharmaceutical industry strives to build an inclusive partner ecosystem that integrates technology, data, and regulatory standardization-enabled innovation into clinical trial delivery. This transformation aims to reduce the burden on investigators and sites while improving the efficiency and accuracy of adverse event (AE) tracking. Driv...

The US and European mammalian contract development and manufacturing organization (CDMO) market is entering a new phase of strategic evolution, driven by accelerating biologics outsourcing, increasing molecule complexity, and growing demand for resilient, end-to-end manufacturing partnerships. As monoclonal antibodies, bispecific antibodies, Fc-fus...

This Frost Radar™ analyzes the competitive landscape of the antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) market. Companies provide the foundational manufacturing and development services for what has become one of the most dynamic and valuable therapeutic modalities in oncology. The success of the ADC rev...

Viral vectors are a critical part of gene therapies and genetic medicines, which are the cornerstone of precision medicines to cure rare diseases, cancers, and genetic disorders. Traditional bioprocessing, however, is tedious, less flexible, batch-based, and heavily manual; as a result, manufacturing processes involve high costs, scalability issues...

Biologics, particularly peptide and protein therapies, are a rapidly growing therapeutic area because they can target complex biological pathways with high efficacy. These therapies are becoming important in oncology, metabolic disease, and autoimmune conditions supported by the growing global disease burden and growth in areas such as GLP-1s and m...

The evolving IT landscape has played a transformative role in the field of life sciences, enabling a reliance on real-world evidence (RWE) solutions. With growing competition and the demand for precision in decision-making, pharmaceutical companies, healthcare providers, and technology organizations have realized the need for real-world data (RWD) ...

Programmable epigenome editing is developing as a distinct approach to controlling gene activity without changing the underlying DNA sequence. This report examines the landscape from the core editing technologies and delivery systems through the companies, academic programs and therapeutic applications shaping the field. It assesses the competitive...